These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 8205277)
1. Coronary heart disease and estrogen replacement therapy. Can compliance bias explain the results of observational studies? Petitti DB Ann Epidemiol; 1994 Mar; 4(2):115-8. PubMed ID: 8205277 [TBL] [Abstract][Full Text] [Related]
2. Estrogen replacement therapy and the prevention of coronary heart disease in postmenopausal women. Contreras I; Parra D Am J Health Syst Pharm; 2000 Nov; 57(21):1963-8; quiz 1969-71. PubMed ID: 11094650 [TBL] [Abstract][Full Text] [Related]
3. Reconciling the divergent findings from clinical trials and observational studies of menopausal hormone therapy for prevention of coronary heart disease. Rossouw JE Semin Reprod Med; 2014 Nov; 32(6):426-32. PubMed ID: 25321419 [TBL] [Abstract][Full Text] [Related]
4. The discrepancy between observational studies and randomized trials of menopausal hormone therapy: did expectations shape experience? Col NF; Pauker SG Ann Intern Med; 2003 Dec; 139(11):923-9. PubMed ID: 14644895 [TBL] [Abstract][Full Text] [Related]
5. Prior to use of estrogen replacement therapy, are users healthier than nonusers? Matthews KA; Kuller LH; Wing RR; Meilahn EN; Plantinga P Am J Epidemiol; 1996 May; 143(10):971-8. PubMed ID: 8629615 [TBL] [Abstract][Full Text] [Related]
6. Hormone replacement therapy and coronary heart disease: results of randomized trials. Petitti D Prog Cardiovasc Dis; 2003; 46(3):231-8. PubMed ID: 14685941 [TBL] [Abstract][Full Text] [Related]
7. Estrogen replacement therapy following oophorectomy in women with a family history of ovarian cancer. Eltabbakh GH; Piver MS; Hempling RE; Recio FO; Aiduk C Gynecol Oncol; 1997 Jul; 66(1):103-7. PubMed ID: 9234929 [TBL] [Abstract][Full Text] [Related]
8. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. Shlipak MG; Simon JA; Vittinghoff E; Lin F; Barrett-Connor E; Knopp RH; Levy RI; Hulley SB JAMA; 2000 Apr; 283(14):1845-52. PubMed ID: 10770146 [TBL] [Abstract][Full Text] [Related]
9. Thrombosis prevention trial: compliance with warfarin treatment and investigation of a retained effect. Rudnicka AR; Ashby D; Brennan P; Meade T Arch Intern Med; 2003 Jun; 163(12):1454-60. PubMed ID: 12824095 [TBL] [Abstract][Full Text] [Related]
10. Hormone replacement therapy, heart disease, and other considerations. Barrett-Connor E; Grady D Annu Rev Public Health; 1998; 19():55-72. PubMed ID: 9611612 [TBL] [Abstract][Full Text] [Related]
11. Hormone replacement therapy and the association with coronary heart disease and overall mortality: clinical application of the timing hypothesis. Hodis HN; Mack WJ J Steroid Biochem Mol Biol; 2014 Jul; 142():68-75. PubMed ID: 23851166 [TBL] [Abstract][Full Text] [Related]
12. Recent epidemiological evidence relevant to the clinical management of the menopause. Shapiro S Climacteric; 2007 Oct; 10 Suppl 2():2-15. PubMed ID: 17882666 [TBL] [Abstract][Full Text] [Related]
13. Hormones and heart disease in women: Heart and Estrogen/Progestin Replacement Study in perspective. Barrett-Connor E; Stuenkel C J Clin Endocrinol Metab; 1999 Jun; 84(6):1848-53. PubMed ID: 10372673 [TBL] [Abstract][Full Text] [Related]
14. Pulse pressure and cardiovascular events in postmenopausal women with coronary heart disease. Nair GV; Chaput LA; Vittinghoff E; Herrington DM; Chest; 2005 May; 127(5):1498-506. PubMed ID: 15888820 [TBL] [Abstract][Full Text] [Related]
15. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). Grady D; Herrington D; Bittner V; Blumenthal R; Davidson M; Hlatky M; Hsia J; Hulley S; Herd A; Khan S; Newby LK; Waters D; Vittinghoff E; Wenger N; JAMA; 2002 Jul; 288(1):49-57. PubMed ID: 12090862 [TBL] [Abstract][Full Text] [Related]
17. Estrogen replacement therapy is underutilized among postmenopausal women at high risk for coronary heart disease. Massey CV; Hupp CH; Kreisberg M; Alpert MA; Hoff C Am J Med Sci; 2000 Aug; 320(2):124-7. PubMed ID: 10981488 [TBL] [Abstract][Full Text] [Related]
18. Effect of age on the exercise response in normal postmenopausal women during estrogen replacement therapy. Seminario NA; Sciacca RR; DiTullio MR; Homma S; Giardina EG J Womens Health Gend Based Med; 1999 Dec; 8(10):1273-9. PubMed ID: 10643835 [TBL] [Abstract][Full Text] [Related]
19. Postmenopausal hormone therapy and atherosclerotic disease. Manson JE Am Heart J; 1994 Dec; 128(6 Pt 2):1337-43. PubMed ID: 7977016 [TBL] [Abstract][Full Text] [Related]
20. The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: the Heart and Estrogen-Progestin Replacement Study (HERS). Simon JA; Lin F; Vittinghoff E; Bittner V; Ann Epidemiol; 2006 Feb; 16(2):138-45. PubMed ID: 16039873 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]